We randomized 187 remitted recurrently depressed adult patients in the Netherlands to either a brief CBT module designed to prevent recurrence, or treatment as usual. 7,8 Primary outcome was time to recurrence, as assessed prospectively over 5.5 years using the Structured Clinical Interview for DSM-IV. This intervention was effective in preventing recurrence over 5.5 years. 8 We used Cox proportional hazard regression analysis to examine whether patients with the short--short allele responded better to CBT (time to recurrence). From 137 patients, we extracted genomic DNA from blood using established procedures. Patients provided informed consent. In order to perform intention-to-treat analyses, we imputed missing data (26.7%) using multiple imputation. We focused on 180 Caucasians (nonCaucasians N ¼ 7). The 5HTTLPR genotypes were in Hardy--Weinberg equilibrium.
We used Cox proportional hazard regression analysis to examine whether patients with the short--short allele responded better to CBT (time to recurrence). From 137 patients, we extracted genomic DNA from blood using established procedures. Patients provided informed consent. In order to perform intention-to-treat analyses, we imputed missing data (26.7%) using multiple imputation. We focused on 180 Caucasians (nonCaucasians N ¼ 7). The 5HTTLPR genotypes were in Hardy--Weinberg equilibrium.
As reported before, 7, 8 Cox regression intention-to-treat analyses revealed that CBT had a preventive effect on time to recurrence, that increased with increasing number of previous episodes (interaction between previous episodes and treatment condition for Caucasian sample: Wald statistic (1, N ¼ 180) ¼ 7.855, Po0.05, hazard ratio ¼ 0.567, 95% confidence interval (CI) ¼ 0.381--0.843. For the total sample: Wald statistic(1, N ¼ 187) ¼ 9.150, Po0.05, hazard ratio adj ¼ 0.547, 95% CI ¼ 0.370--0.809).
The genotyping success rate was 99.3%. Genotype distribution for the Caucasian subset (whole sample) was as follows; LL: 29.1% (28.3%); LS: 52.8% (53.5%); SS: 17.9% (17.7%). Over 5.5 years of follow-up, 76.7% (138/180) experienced a recurrence (75.2% in SS, 77.3% in SL/LL). In the total sample, recurrence rates were 76.1% in SS and 77.6% in SL/LL. As shown in Figure 1 , the 5HTTLPR was not significantly associated with treatment response (no significant treatment condition Â 5HTTLPR Â number of previous episodes interaction effect on time to recurrence; interaction term for Caucasian sample: Wald statistic (1, N ¼ 180) ¼ 0.717, P ¼ 0.418, hazard ratio ¼ 0.271, 95% CI ¼ 0.009--8.560).
We found comparable results controlling for age and gender We could not corroborate the preliminary findings 6 that 5HTTLPR is associated with response to CBT. Apart from 5HTTLPR, several other polymorphisms (and potentially their interactions) might be associated with treatment response. 2 This finding could also indicate that 5HTTLPR does predict CBT response in one population (children with anxiety disorders), but not in the other (recurrently depressed adults). Unfortunately, our sample size is relatively small, therefore additional studies are needed. Clinical trials are necessary to explore whether genetic profiles indeed can be useful biomarkers of psychological treatment outcomes to enhance better patient--treatment matching in psychiatric illnesses.
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). Here, we provide evidence from a population-based study, Generation Scotland--Scottish Family Health Study (GS:SFHS 2 ), for association between singlenucleotide polymorphisms (SNPs) in DISC1 and recurrent major depression (RMD). In addition, two recent publications identified SNPs that tag cis-acting factors affecting expression of DISC1 (eQTLs, expression quantitative trait loci).
3,4 Here, we show that these eQTLs are associated with age of onset, indicating that DISC1 expression levels may be linked to phenotype severity.
DISC1 was first implicated in RMD in a Scottish family with a translocation, t(1:11) (q42.1;q14.3), that interrupts the DISC1 gene resulting in an approximately 50% reduction in DISC1 expression in lymphoblastoid cell lines derived from translocation carriers. Thirty-four percent of the translocation carriers were diagnosed with RMD, 24% received a diagnosis of schizophrenia or bipolar disorder, giving a significant logarithm of odds (LOD) score of 4.5 for RMD alone. 5 Association between DISC1 and RMD was subsequently also reported in case--control cohorts. 4, 6, 7 GS:SFHS is a voluntary study of participants, invited via their general medical practitioner, and their relatives (full protocol in 2 ), total sample size B24 000. They were not selected on any clinical diagnosis. Ethical approval for the GS:SFHS was obtained from the Tayside Committee on Medical Research Ethics. All individuals were screened for RMD DSM-IV (SCID 8 ). In total, 17 SNPs with prior evidence of association with psychiatric illness (Supplementary Table 1 ) were genotyped at the Wellcome Trust Clinical Research Facility Edinburgh on an ABI OpenArray. This sample consisted of 475 cases of RMD (157 males, 318 females) and 475 age and sex-matched unrelated GS:SFHS controls (who screened negative for any mental disorder). Individuals were also assessed for a comprehensive battery of psychiatric and cognitive phenotypes (Supplementary Table 2 ), although, as both Mood Disorder Questionnaire (MDQ) and Schizotypal Personality Questionnaire (SPQ-B) were added to the testing battery at a later date, fewer individuals had data for these variables. Association analysis was performed in PLINK v1.07 with age and/or sex fitted as covariates as appropriate. Owing to the prior results of sex-specific associations in DISC1, both gender-specific and combined case--control analyses were performed. SNP and haplotype effect sizes (proportion of the variance explained, partial Z 2 ) were calculated by analysis of variance with sex as a fixed factor (SPSS 14.0.1, SPSS Inc., Chicago, IL, USA).
Consistent with previous results, 1 two SNPs in DISC1 showed sex-specific association with RMD; a nonsynonymous SNP in exon 2, rs3738401, was associated in the female subset (P ¼ 0.023) and a SNP in the exon 13 3 0 UTR, rs3737597, was associated in both males and the combined group (P ¼ 0.016 and P ¼ 0.023, respectively; Table 1 ). No significant results were found for the cognitive variables when cases and controls were analysed together (with age, sex and diagnosis as covariates, P40.001 the Bonferroni corrected significance threshold). However, a single SNP in intron 1, rs6541281, was associated with age of onset (P ¼ 0.00083, N ¼ 442; Table 1 ). Nominal significance was also seen with the neighbouring exon 2 SNP rs3738401 and age of onset (P ¼ 0.048). Strikingly, these SNPs have previously been associated with reduced DISC1 expression levels in two studies (B20% reduction 3, 4 ) and are on the same CEU D 0 haplotype block. Together, these data are consistent with a 5 0 haplotype that tags a cis-acting modifier of DISC1 expression. To examine this further, we undertook haplotype analysis of the two associated SNPs, rs6541281 and rs3738401, and detected a TG haplotype that was significantly associated with a reduced age of onset (P ¼ 0.0013, partial Z 2 ¼ 0.024, freq ¼ 0.445). This haplotype was not associated with diagnosis per se (P ¼ 0.17).
The power of this study is limited compared with the large GWAS meta-analysis studies currently underway. However, our ability to detect association may be improved by the relative homogeneity of the Scottish population. Assuming a type I error rate of 0.05, we have a 480% power to detect an allele with minor allele frequency (MAF) of 0.30, odds ratio (OR) 1.3 at Po0.05; or MAF 0.03, OR 1.8 at Po0.05 for RMD (see Table 1 for the MAF of SNPs used in this study). We have 80% power to detect a variant explaining 2% of the phenotypic variance for the cognitive traits, 38% power to detect a variant explaining 1% of the phenotypic variance, this is further reduced to 52% power to detect a variant explaining 2% of the phenotypic variance for SPQ-B and MDQ scores. In line with the recent mega-analysis in depression, 11 we have 35% power to detect an allele with MAF 0.30, OR 1.15 at Po0.05. Although we note that substantially larger OR have been detected for recurrent early onset major depression such as that tested here. 11, 12 Early age of onset is typically associated with a more severe phenotype, increased familiarity and with treatment-resistant forms of psychiatric illness. 9 Interestingly, Hennah and Porteous 3 noted a highly significant association between eQTLs in the DISC1 pathway and modulation of psychiatric drug targets. Recently, rs3738401 has been shown to be associated with treatment-resistant schizophrenia in French Caucasian patients, but not in French Algerian. , proportion of variance explained by the SNP on age of onset; Pos, position in the full-length DISC1 isoform L; P-val, P-values for association with recurrent major depression in males and females combined (M þ F) and separately (M, F). Bold values are with Po0.05.
Letters to the Editor
In conclusion, our study of DISC1 variants in an extensively phenotyped, population-based sample from the Scottish population has provided further evidence of association between DISC1 and RMD and for an effect of expression level on age of onset. These results, and the reduced level of DISC1 expression in translocation carriers from the t(1:11) family, suggests that modulation of DISC1 expression is a consistent mechanism for elevated risk to neuronal dysfunction and psychiatric illness. Further confirmatory studies, ideally on samples with both comprehensive clinical and expression data are warranted.
